Literature DB >> 16936989

[Lipid profile of patients with increased risk for cardiovascular events in daily clinical practice].

Rodrigo O Moreira1, Raul D Santos, Lilton Martinez, Fabiana C Saldanha, Jara Lucia A C Pimenta, Josefina Feijoo, Natalie Jahnke, Otávio C Mangile, Rosane Kupfer.   

Abstract

Although there are specific guidelines regarding the treatment of dyslipidemia in highly risk patients, these recommendations are usually inadequately followed. The aim of this study is to investigate risk factors in patients with increased cardiovascular risk currently treated in Brazil and Venezuela. Medical charts of 412 patients were selected in 4 institutions. Patients were divided into groups according to the use of lipid-lowering drugs (LLD), particularly statins. Patients who did not use LLD showed higher levels of total cholesterol (p< 0.001), LDL cholesterol (p< 0,001) and HDL cholesterol (p< 0.001), besides lower levels of triglycerides (p< 0.001). The use of statins was associated with a decrease in levels of total cholesterol (from 251.0 +/- 40.0 to 196.0 +/- 46.0), LDL cholesterol (from 168.0 +/- 36.0 to 116.0 +/- 39.0), HDL cholesterol (from 51.0 +/- 46.0 to 46.0 +/- 12.0) and triglycerides (from 181.0 +/- 120.0 to 160.0 +/-79.0). Finally, only a small percentage of patients, even those under treatment with LLD, showed cholesterol levels according to currently available guidelines. Therefore, although the guidelines for the treatment of dyslipidemia are widely known, only a small percentage of patients achieve adequate levels of cholesterol. It is necessary to decrease lipid levels of these patients by increasing the dose of the statins or using a second drug.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16936989     DOI: 10.1590/s0004-27302006000300011

Source DB:  PubMed          Journal:  Arq Bras Endocrinol Metabol        ISSN: 0004-2730


  1 in total

1.  Comorbidities Associated with Obstructive Sleep Apnea: a Retrospective Study.

Authors:  José Antonio Pinto; Davi Knoll Ribeiro; Andre Freitas da Silva Cavallini; Caue Duarte; Gabriel Santos Freitas
Journal:  Int Arch Otorhinolaryngol       Date:  2016-03-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.